Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Gains from Investment Securities (2016 - 2025)

Dexcom (DXCM) has disclosed Gains from Investment Securities for 14 consecutive years, with $20.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 70.65% to $20.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.8 million, a 73.19% decrease, with the full-year FY2025 number at $21.8 million, down 73.19% from a year prior.
  • Gains from Investment Securities was $20.4 million for Q4 2025 at Dexcom, up from -$11.3 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $69.5 million in Q4 2024 to a low of -$48.1 million in Q4 2021.
  • A 5-year average of $8.8 million and a median of $4.4 million in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 5130.77% in 2023; the steepest drop was 11000.0% in 2023.
  • Dexcom's Gains from Investment Securities stood at -$48.1 million in 2021, then soared by 97.3% to -$1.3 million in 2022, then skyrocketed by 5130.77% to $65.4 million in 2023, then grew by 6.27% to $69.5 million in 2024, then tumbled by 70.65% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Gains from Investment Securities are $20.4 million (Q4 2025), -$11.3 million (Q3 2025), and $11.6 million (Q2 2025).